Prescription digital therapeutics (PDTx) encompass software-based treatments designed to address various illnesses. With the merging of technology and biology, prescription digital medications have emerged as a novel category of therapeutic tools. These innovative solutions leverage artificial intelligence, algorithms, and virtual reality to deliver direct treatments for critical disorders comparable to traditional biologics or medications. PDTx represents an exciting advancement at the intersection of healthcare and technology, revolutionizing the treatment landscape.
According to Data Bridge Market Research the Prescription Digital Therapeutics (PDTx) Market accounted for USD 3.90 billion in 2022, and expected to reach USD 17.16 billion by 2030. The market is expected to grow with a CAGR of 20.35% in the forecast period of 2023 to 2030.
“Rising chronic diseases will bolster the growth”
The increasing number of chronic diseases is a key driver for the growth of the prescription digital therapeutics (PDTx) market in the projected period of 2022–2029. As per the World Health Organization (WHO), the number of individuals with diabetes is projected to reach 463 million in 2020, and it is anticipated that the global diabetic population will reach around 629 million by 2045. This significant rise in chronic disorders underscores the growing demand and potential for PDTx solutions, contributing to the market’s growth.
What restraints the growth of the prescription digital therapeutics (PDTx) market?
“Privacy and security will hinder the market growth”
Concerns over privacy and security may hinder the market growth of prescription digital therapeutics (PDTx). As PDTx involves using digital platforms to deliver therapeutic interventions, there is a risk of unauthorized access to sensitive patient data. This raises concerns about privacy breaches and potential misuse of personal health information. Such apprehensions can deter individuals from adopting PDTx solutions and pose regulatory challenges, thereby impeding market growth in the field.
Segmentation: Prescription Digital Therapeutics (PDTx) Market
The prescription digital therapeutics (PDTx) market is segmented on the basis of mechanism, category, treatment, software, services, app accessibility, app type, application, and patients.
- On the basis of mechanism, the prescription digital therapeutics (PDTx) market has been segmented into input mechanisms and output mechanisms.
- On the basis of category, the prescription digital therapeutics (PDTx) market has been segmented into medication augmentation and medication replacement.
- On the basis of treatment, the prescription digital therapeutics (PDTx) market has been segmented into outpatient treatment and monotherapy.
- On the basis of software, the prescription digital therapeutics (PDTx) market has been segmented into software for respiratory conditions, software for mental health, software for opioid use disorder, software for diabetes, and others.
- On the basis of services, the prescription digital therapeutics (PDTx) market has been segmented into behavioral microservices and medical microservices.
- On the basis of app accessibility, the prescription digital therapeutics (PDTx) market has been segmented into android, ios, and windows.
- On the basis of app type, the prescription digital therapeutics (PDTx) market has been segmented into native apps, and web apps.
- On the basis of application, the prescription digital therapeutics (PDTx) market has been segmented into substance use disorder (SUD), Opioid Use Disorder (OUD), attention deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, major depressive disorder (MDD), Insomnia epilepsy, movement disorder, multiple sclerosis, migraine, autism spectrum disorder, oncology, inflammation, respiratory, cardiovascular, pain management, metabolic conditions, others.
- On the basis of patients, the prescription digital therapeutics (PDTx) market has been segmented into children, and adults.
Regional Insights: North America Dominates the Prescription Digital Therapeutics (PDTx) Market
North America dominates the prescription digital therapeutics (PDTx) market due to increased research and development activities and a rise in healthcare spending. Furthermore, the market will experience a boost in growth from the expansion of established companies and the entry of new startups in this field. These factors collectively contribute to the positive trajectory and advancement of the PDTx market.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the increasing healthcare costs and the escalating prevalence of chronic diseases in the region. Furthermore, advancements in payment systems for digital therapies can potentially accelerate the growth of the market. These factors combined contribute to the favorable conditions for expanding and adopting PDTx solutions in the healthcare industry.
To know more about the study visit, https://www.databridgemarketresearch.com/pt/reports/global-prescription-digital-therapeutics-dtx-market
Recent Development
- In 2020, Reset prescription digital therapies have announced market approval from Singapore's Health Science Authority for treating people with substance use disorders, according to Pear Therapeutics, Inc.
The Prominent Key Players Operating in the Prescription Digital Therapeutics (PDTx) Market Include:
- ResMed (U.S.)
- SAMSUNGHEALTHCARE (South Korea)
- Biofourmis (US)
- Novartis AG (Switzerland)
- Medtronic (Ireland)
- Pear Therapeutics, Inc. (U.S.)
- Voluntis (France)
- Omada Health, Inc. (U.S.)
- GAIA AG (Germany)
- Welldoc’s Bluestar (U.S.)
- Solera Network (U.S.)
- Akili Interactive Labs, Inc. (U.S.)
- Better Therapeutics, LLC (U.S.)
- BigHealth (U.S.)
- Biofourmis (U.S.)
- Click Therapeutics, Inc. (U.S.)
- Happify, Inc. (U.S.)
- Limbix Health, Inc. (U.S.)
- Naturalcycles Nordic AB (Sweden)
- NuvoAir AB (Sweden)
- Sensyne Health plc. (U.K.)
- Xealth (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of prescription digital therapeutics (PDTx) market companies contact, https://www.databridgemarketresearch.com/pt/contact
Research Methodology: Global Prescription Digital Therapeutics (PDTx) Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
